Highlights ESSA Pharma Inc. Toronto S.E.

Equities

CA29668H7085

End-of-day quote Toronto S.E. Other stock markets			5-day change	1st Jan Change
- ^CAD	-.--%		-.--%	-.--%

May. 20	Top Premarket Decliners	MT
May. 14	ESSA Pharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Top Premarket Decliners	May. 20	MT
ESSA Pharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	May. 14	CI
Norway's wealth fund pushes for more women on emerging market company boards	Mar. 06	RE
ESSA Pharma Inc. Reports Earnings Results for the Fourth Quarter Ended September 30, 2023	Dec. 12	CI
ESSA Pharma Inc. Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 30th Annual Prostate Cancer Foundation Scientific Retreat	23-10-26	CI
ESSA Pharma Inc. Announces Initiation of Phase 2 Study Evaluating Masofaniten (EPI-7386) in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer	23-09-18	CI
ESSA Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	23-08-08	CI
ESSA Pharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	23-05-09	CI
ESSA Pharma Inc. Announces Clinical Trial Support Agreement with Janssen Research & Development, LLC	23-04-12	CI
ESSA Pharma Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022	23-02-07	CI
Earnings Flash (EPIX) ESSA PHARMA Posts Q4 Loss $-0.14	22-12-13	MT
ESSA Pharma Inc. Reports Earnings Results for the Fourth Quarter Ended September 30, 2022	22-12-13	CI
ESSA Pharma Inc. Reports Earnings Results for the Full Year Ended September 30, 2022	22-12-13	CI
ESSA Pharma Inc. Provides an Update on Its Clinical Collaboration with Janssen	22-10-31	CI
Health Care Up After Bristol Myers Earnings -- Health Care Roundup	22-10-26	DJ
ESSA Pharma Inc. Announces Updated Results from the Phase 1/2 Study of ESSA's Lead Candidate EPI-7386 in Combination with Enzalutamide Highlighted at the 29th Annual Prostate Cancer Foundation Scientific Retreat	22-10-26	CI
ESSA Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2022	22-08-04	CI
Earnings Flash (EPIX) ESSA PHARMA Reports Q3 Loss $-0.20	22-08-04	MT
ESSA Pharma Presents Clinical Update on EPI-7386 Monotherapy and Combination Therapy Clinical Development	22-06-27	CI
Earnings Flash (EPIX) ESSA PHARMA Posts Q1 Loss $-0.25	22-05-10	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights ESSA Pharma Inc. Toronto S.E.

Equities

CA29668H7085

Highlights

Filters